The Vision Correction Comeback Story Starting to Look Real Again

30‑Second Take

STAAR Surgical Company (NASDAQ: STAA) is starting to look like a medical technology turnaround story with real momentum behind it again. The latest quarter was dramatically stronger than expected, with revenue surging 120% year over year as China demand stabilized, EVO+ lens adoption accelerated, and profitability returned far faster than the market anticipated.

What makes the setup interesting is that the stock still looks like it is rebuilding trust after the disruptions of 2025. Management believes many of those operational and inventory issues are now behind the company, while growth in both China and the U.S. is improving, and margins are expanding.

Trade Setup

Time frame: Medium-to-long term

Edge type: Operational recovery meets growth rerating

The opportunity here is that the market is reassessing STAAR as a scaling premium medical technology business again, rather than a company trapped in post-China disruption cleanup mode.

If procedure growth, EVO+ adoption, and margin expansion continue to improve together, the earnings recovery could still be ahead of investor expectations today.

Snapshot Table

Chart

1-month trading summary: STAAR has spent the last month acting like a stock rebuilding institutional confidence after a major reset. Shares climbed almost 29%, with momentum accelerating sharply following the company's blowout earnings report and stronger-than-expected recovery in both revenue and margins.

What stands out on the chart is how quickly buyers stepped back in once the market realized the turnaround was becoming operational rather than narrative-driven.

The stock is now pushing toward the upper end of its 52-week range again, suggesting investors are starting to price in the possibility that STAAR’s growth engine is reaccelerating faster than many expected.

Bull Case 

A premium vision correction story rebuilding momentum: The bull case for STAAR is that the company is moving back toward being a high-growth premium medical technology story rather than a business stuck in recovery mode.

EVO lens adoption continues to expand, the refractive surgery market remains significantly underpenetrated, and the company is benefiting from growing demand for premium alternatives to traditional laser procedures.

What makes this opportunity especially interesting is the model's scalability. If procedure growth continues accelerating, earnings leverage can improve quickly because much of the infrastructure is already in place. That creates room for STAAR to potentially shift from a turnaround narrative back into a durable growth story over the next few quarters.

The turnaround is starting to look real: One of the biggest catalysts is that many of the issues that damaged investor confidence previously are now stabilizing. Management says China inventory levels have normalized, commercial execution in the U.S. is improving, and manufacturing efficiency is strengthening as the Swiss facility scales production.

The other major driver is EVO+ adoption. Early demand has been strong, customers are accepting the premium pricing, and the company is beginning to show the kind of operating leverage that can materially change earnings power if growth continues to accelerate.

If that momentum holds over the next few quarters, the market may start treating STAAR less like a recovery trade and more like a premium-growth medtech story again.

Wall Street still sees room higher: Analyst price targets currently range from around $23 on the low end to $40 on the high end, reflecting a market still debating whether STAAR is simply recovering or returning to a sustainable growth trajectory.

Technical tailwinds: Momentum has improved dramatically since earnings, with STAAR breaking higher on heavy buying volume and reclaiming levels the stock struggled to hold earlier in the year. The chart is starting to look more like a sustained recovery trend than a short-term bounce.

Bear Case 

Execution still matters here: The biggest risk is that the recovery loses momentum before investor confidence is fully rebuilt. STAAR still depends heavily on procedure growth in China, and this remains a premium elective medical purchase that can soften if consumer sentiment weakens or competitive pressure increases.

There is also very little room for operational mistakes after the volatility of the last two years. If growth slows again or inventory issues reappear, the market could quickly shift back toward questioning whether the business deserves a premium growth valuation at all.

Competition is getting smarter: STAAR still has a differentiated position in implantable lenses, but the broader vision correction market is highly competitive. Traditional LASIK providers remain deeply entrenched, while larger ophthalmology players continue investing in premium refractive technologies and surgical innovation.

The challenge is maintaining premium positioning as the category grows. If competitors narrow the technology gap or pricing pressure increases, STAAR may find it harder to sustain the kind of growth and margins investors are now starting to expect again.

Elective procedure spending can swing quickly: STAAR operates in a part of healthcare still influenced by consumer confidence and discretionary spending. Premium vision correction procedures are not immune to economic slowdowns, especially in key international markets where demand can shift quickly when consumer sentiment weakens.

The company is also exposed to broader geopolitical and regulatory uncertainty tied to China, which remains one of its most important growth markets. Any renewed disruption there would likely have an outsized impact on investor sentiment toward the stock.

Crowded trade concern: Momentum has improved quickly, suggesting expectations are rising again after the post-2025 reset. If growth stays strong, the rerating can continue, but sharp recovery trades like this can also become vulnerable to aggressive pullbacks when sentiment overheats.

Quick Checklist 

✅ Thesis still valid after today’s close
✅ Volume confirms move above key levels
✅ Catalyst date double-checked (May 19, 2026)

Deep‑Dive Links

• Q1 2026 Earnings 

• Analyst Ratings & Price Targets

• Short Interest Data

• Company Profile and Investor Relations

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha